{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T05:07:37Z","timestamp":1784696857901,"version":"3.55.0"},"reference-count":86,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>TP53 mutations are strongly associated with resistance to venetoclax in acute myeloid leukemia (AML) and represent a major challenge in current treatment strategies. Importantly, different TP53 mutants exhibit substantial functional heterogeneity, leading to distinct resistance phenotypes that are not adequately captured by conventional variant allele frequency (VAF)-based stratification. Emerging evidence suggests that TP53 mutations promote venetoclax resistance through multiple mechanisms, including apoptotic dysregulation, metabolic reprogramming, enhancement of leukemic stem cell properties, and epigenetic remodeling, with the relative contribution of each pathway varying among mutant types. This review systematically summarizes recent advances in the molecular mechanisms underlying TP53-mediated venetoclax resistance, with a particular focus on how mutant-specific functional differences shape therapeutic responses. Unlike previous broad reviews of TP53-mutated AML, this article specifically addresses venetoclax resistance as a clinically critical therapeutic challenge. We further discuss the limitations of current VAF-based classification systems and propose a practical framework that integrates mutant-specific resistance biology with precision therapeutic strategies.<\/jats:p>","DOI":"10.3389\/fonc.2026.1921345","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T04:48:58Z","timestamp":1784695738000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Functional heterogeneity of TP53 mutants in venetoclax-resistant AML: mechanisms, clinical implications, and therapeutic opportunities"],"prefix":"10.3389","volume":"16","author":[{"given":"Maierhaba","family":"Maimaitituerhong","sequence":"first","affiliation":[{"name":"School of Basic Medical Sciences, Xinjiang Second Medical College","place":["Karamay, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinling","family":"Xiao","sequence":"additional","affiliation":[{"name":"School of Basic Medical Sciences, Xinjiang Second Medical College","place":["Karamay, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenji","family":"Gao","sequence":"additional","affiliation":[{"name":"School of Basic Medical Sciences, Xinjiang Second Medical College","place":["Karamay, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiqi","family":"Zheng","sequence":"additional","affiliation":[{"name":"School of Basic Medical Sciences, Xinjiang Second Medical College","place":["Karamay, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yage","family":"Fan","sequence":"additional","affiliation":[{"name":"School of Basic Medical Sciences, Xinjiang Second Medical College","place":["Karamay, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Zhang","sequence":"additional","affiliation":[{"name":"School of Basic Medical Sciences, Xinjiang Second Medical College","place":["Karamay, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Hefei first people`s hospital","place":["Hefei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengmei","family":"Deng","sequence":"additional","affiliation":[{"name":"School of Basic Medical Sciences, Chengdu Medical College","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leiming","family":"Xia","sequence":"additional","affiliation":[{"name":"School of Basic Medical Sciences, Xinjiang Second Medical College","place":["Karamay, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"Dohner","year":"2022","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbior.2024.101073","article-title":"TP53 gene status can promote sensitivity and resistance to chemotherapeutic drugs and small molecule signal transduction inhibitors","volume":"95","author":"McCubrey","year":"2025","journal-title":"Adv Biol Regul"},{"key":"B5","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1186\/s40001-025-02571-x","article-title":"Meta-analysis on the effectiveness and safety of venetoclax-based combination therapy with hypomethylation in acute myeloid leukemia","volume":"30","author":"Wang","year":"2025","journal-title":"Eur J Med Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1186\/s12935-025-03858-z","article-title":"Efficacy and prognostic analysis of venetoclax combined with hypomethylating agents for induction therapy in acute myeloid leukemia: a multi-center real-world study on indication-specific stratification, molecular markers, and hematologic toxicities","volume":"25","author":"Xia","year":"2025","journal-title":"Cancer Cell Int"},{"key":"B8","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13045-023-01417-5","article-title":"Treatment outcomes for newly diagnosed, treatment-na\u00efve TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis","volume":"16","author":"Daver","year":"2023","journal-title":"J Hematol Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/s41392-023-01394-8","article-title":"Venetoclax and Azacitidine in Chinese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy","volume":"8","author":"Xia","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2022.101036","article-title":"Acute myeloid leukemia resistant to venetoclax-based therapy: What does the future hold","volume":"59","author":"Dhakal","year":"2023","journal-title":"Blood Rev"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-19-0125","article-title":"The TP53 apoptotic network is a primary mediator of resistance to BCL2 inhibition in AML cells","volume":"9","author":"Nechiporuk","year":"2019","journal-title":"Cancer Discov"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1126\/science.1092734","article-title":"Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis","volume":"303","author":"Chipuk","year":"2004","journal-title":"Science"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1038\/s41467-021-22655-6","article-title":"Structural insight into the molecular mechanism of p53-mediated mitochondrial apoptosis","volume":"12","author":"Wei","year":"2021","journal-title":"Nat Commun"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1101\/gad.190678.112","article-title":"Mutant p53: one name, many proteins","volume":"26","author":"Freed-Pastor","year":"2012","journal-title":"Genes Dev"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1016\/j.celrep.2019.08.061","article-title":"Integrated analysis of TP53 gene and pathway alterations in the cancer genome atlas","volume":"28","author":"Donehower","year":"2019","journal-title":"Cell Rep"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/cdd.2017.180","article-title":"Why are there hotspot mutations in the TP53 gene in human cancers","volume":"25","author":"Baugh","year":"2018","journal-title":"Cell Death Differ"},{"key":"B17","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.molcel.2018.08.013","article-title":"A systematic p53 mutation library links differential functional impact to cancer mutation pattern and evolutionary conservation","volume":"71","author":"Kotler","year":"2018","journal-title":"Mol Cell"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-024-02039-4","article-title":"Deep CRISPR mutagenesis characterizes the functional diversity of TP53 mutations","volume":"57","author":"Funk","year":"2025","journal-title":"Nat Genet"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.08.028","article-title":"Putting p53 in context","volume":"170","author":"Kastenhuber","year":"2017","journal-title":"Cell"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1126\/science.8023157","article-title":"Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations","volume":"265","author":"Cho","year":"1994","journal-title":"Science"},{"key":"B21","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1126\/science.aax3649","article-title":"A dominant-negative effect drives selection of TP53 missense mutations in myeloid Malignancies","volume":"365","author":"Boettcher","year":"2019","journal-title":"Science"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-018-0204-y","article-title":"Mutational processes shape the landscape of TP53 mutations in human cancer","volume":"50","author":"Giacomelli","year":"2018","journal-title":"Nat Genet"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2693","article-title":"When mutants gain new powers: news from the mutant p53 field","volume":"9","author":"Brosh","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2014.01.021","article-title":"Mutant p53 in cancer: new functions and therapeutic opportunities","volume":"25","author":"Muller","year":"2014","journal-title":"Cancer Cell"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.biochem.77.060806.091238","article-title":"Structural biology of the tumor suppressor p53","volume":"77","author":"Joerger","year":"2008","journal-title":"Annu Rev Biochem"},{"key":"B26","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1146\/annurev-biochem-060815-014710","article-title":"The p53 pathway: origins, inactivation in cancer, and emerging therapeutic approaches","volume":"85","author":"Joerger","year":"2016","journal-title":"Annu Rev Biochem"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jcim.5c00580","article-title":"Investigation of structural mechanisms underlying p53 dysfunction caused by 148 missense mutations using alphaFold3 and molecular dynamics simulations","volume":"65","author":"Rustamov","year":"2025","journal-title":"J Chem Inf Model"},{"key":"B28","doi-asserted-by":"publisher","first-page":"4300","DOI":"10.1038\/s41467-023-40087-2","article-title":"Structures of p53\/BCL-2 complex suggest a mechanism for p53 to antagonize BCL-2 activity","volume":"14","author":"Wei","year":"2023","journal-title":"Nat Commun"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2026.1779094","article-title":"Mechanistic overview and suggested strategies to overcome BCL-2 inhibitor resistance in TP53-mutated acute myeloid leukemia","volume":"14","author":"Iqbal","year":"2026","journal-title":"Front Cell Dev Biol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2010.03.082","article-title":"Interference with the p53 family network contributes to the gain of oncogenic function of mutant p53 in hepatocellular carcinoma","volume":"394","author":"Schilling","year":"2010","journal-title":"Biochem Biophys Res Commun"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2016.312","article-title":"Neomorphic mutations create therapeutic challenges in cancer","volume":"36","author":"Takiar","year":"2017","journal-title":"Oncogene"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022019047","article-title":"Epichaperome inhibition targets TP53-mutant AML and AML stem\/progenitor cells","volume":"142","author":"Carter","year":"2023","journal-title":"Blood"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2023.06.048","article-title":"Mitophagy promotes resistance to BH3 mimetics in acute myeloid leukemia","volume":"13","author":"Glytsou","year":"2023","journal-title":"Cancer Discov"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2006.05.036","article-title":"TIGAR, a p53-inducible regulator of glycolysis and apoptosis","volume":"126","author":"Bensaad","year":"2006","journal-title":"Cell"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgaf027","article-title":"Somatic p53 mutations that are markedly overrepresented in lung cancer confer resistance to reactive oxygen species-induced cell death","volume":"46","author":"Tracewell","year":"2025","journal-title":"Carcinogenesis"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-020-00126-z","article-title":"Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells","volume":"1","author":"Stevens","year":"2020","journal-title":"Nat Cancer"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.bneo.2025.100121","article-title":"PPAR\u03b3-induced upregulation of fatty acid metabolism confers resistance to venetoclax and decitabine therapy in AML","volume":"2","author":"Yamatani","year":"2025","journal-title":"Blood Neoplasia"},{"key":"B38","doi-asserted-by":"publisher","first-page":"5709","DOI":"10.1038\/s41467-023-41229-2","article-title":"ABCC1 and glutathione metabolism limit the efficacy of BCL-2 inhibitors in acute myeloid leukemia","volume":"14","author":"Ebner","year":"2023","journal-title":"Nat Commun"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01295-1","article-title":"Genomic analysis of cellular hierarchy in acute myeloid leukemia using ultrasensitive LC-FACSeq","volume":"35","author":"Saygin","year":"2021","journal-title":"Leukemia"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/ncb1211","article-title":"p53 induces differentiation of mouse embryonic stem cells by suppressing Nanog expression","volume":"7","author":"Lin","year":"2005","journal-title":"Nat Cell Biol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40164-026-00751-x","article-title":"Single-cell profiling reveals reprogrammed hierarchy and disrupted immune-stromal ecosystem in TP53-mutated AML","volume":"15","author":"Qiu","year":"2026","journal-title":"Exp Hematol Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0233-1","article-title":"Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia","volume":"24","author":"Pollyea","year":"2018","journal-title":"Nat Med"},{"key":"B43","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/s41419-025-07560-w","article-title":"Targeting METTL3 mitigates venetoclax resistance via proteasome-mediated modulation of MCL1 in acute myeloid leukemia","volume":"16","author":"Jiao","year":"2025","journal-title":"Cell Death Dis"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/emboj.2009.395","article-title":"Coordinated regulation of p53 apoptotic targets BAX and PUMA by SMAR1 through an identical MAR element","volume":"29","author":"Sinha","year":"2010","journal-title":"EMBO J"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0045571","article-title":"A novel small molecule FL118 that selectively inhibits survivin, Mcl-1, XIAP and cIAP2 in a p53-independent manner, shows superior antitumor activity","volume":"7","author":"Ling","year":"2012","journal-title":"PloS One"},{"key":"B46","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41420-025-02446-4","article-title":"Enhancing venetoclax efficacy in leukemia through association with HDAC inhibitors","volume":"11","author":"Carlos","year":"2025","journal-title":"Cell Death Discov"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.bneo.2024.100004","article-title":"Comparison of TP53 mutations in myelodysplasia and acute leukemia suggests divergent roles in initiation and progression","volume":"1","author":"Jambhekar","year":"2024","journal-title":"Blood Neoplasia"},{"key":"B48","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/s41408-024-01186-5","article-title":"What have we learned about TP53-mutated acute myeloid leukemia","volume":"14","author":"Shahzad","year":"2024","journal-title":"Blood Cancer J"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2025.297","article-title":"Prognostic landscape of TP53 mutations in hematologic Malignancies","volume":"58","author":"Jang","year":"2026","journal-title":"Cancer Res Treat"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014472","article-title":"Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome","volume":"139","author":"Grob","year":"2022","journal-title":"Blood"},{"key":"B51","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1136\/jmedgenet-2020-107059","article-title":"Blood functional assay for rapid clinical interpretation of germline TP53 variants","volume":"58","author":"Raad","year":"2021","journal-title":"J Med Genet"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2018.09.010","article-title":"Patterns of mutations in TP53 mutated AML","volume":"31","author":"Welch","year":"2018","journal-title":"Best Pract Res Clin Haematol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-140182","article-title":"Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclax","volume":"127","author":"Kim","year":"2021","journal-title":"Cancer"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.m109.081042","article-title":"Regulation of mitochondrial apoptotic events by p53-mediated disruption of complexes between antiapoptotic Bcl-2 members and Bim","volume":"285","author":"Han","year":"2010","journal-title":"J Biol Chem"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1042\/bj20131438","article-title":"Drp1 stabilizes p53 on the mitochondria to trigger necrosis under oxidative stress conditions in vitro and in vivo","volume":"461","author":"Guo","year":"2014","journal-title":"Biochem J"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70164","article-title":"Long-term follow-up and combined Phase 2 results of eprenetapopt and azacitidine in patients with TP53 mutant MDS\/AML","volume":"9","author":"Sallman","year":"2025","journal-title":"Hemasphere"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-24-1421","article-title":"Restoration of the tumor suppressor function of Y220C-mutant p53 by rezatapopt, a small-molecule reactivator","volume":"15","author":"Puzio-Kuter","year":"2025","journal-title":"Cancer Discov"},{"key":"B58","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1158\/2159-8290.cd-22-0381","article-title":"A small molecule reacts with the p53 somatic mutant Y220C to rescue wild-type thermal stability","volume":"13","author":"Guiley","year":"2023","journal-title":"Cancer Discov"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.5483\/bmbrep.2014.47.3.261","article-title":"Structural insights into the transcription-independent apoptotic pathway of p53","volume":"47","author":"Chi","year":"2014","journal-title":"BMB Rep"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.02341","article-title":"Eprenetapopt (APR-246) and azacitidine in TP53-mutant myelodysplastic syndromes","volume":"39","author":"Sallman","year":"2021","journal-title":"J Clin Oncol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1093\/jmcb\/mjaa040","article-title":"Gain-of-function mutant p53 in cancer progression and therapy","volume":"12","author":"Zhang","year":"2020","journal-title":"J Mol Cell Biol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10071490","article-title":"P63 and P73 activation in cancers with p53 mutation","volume":"10","author":"Cai","year":"2022","journal-title":"Biomedicines"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/cdd.2011.71","article-title":"SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis","volume":"18","author":"Li","year":"2011","journal-title":"Cell Death Differ"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.02604","article-title":"Tolerability and efficacy of the anticluster of differentiation 47 antibody magrolimab combined with azacitidine in patients with previously untreated AML: Phase Ib results","volume":"41","author":"Daver","year":"2023","journal-title":"J Clin Oncol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2025.289205","article-title":"Clinical interrogation of TP53 aberrations and its impact on survival in patients with myeloid neoplasms","volume":"110","author":"Senapati","year":"2025","journal-title":"Haematologica"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.2147\/ott.s172315","article-title":"MDM2 antagonists as a novel treatment option for acute myeloid leukemia: Perspectives on the therapeutic potential of idasanutlin (RG7388)","volume":"12","author":"Khurana","year":"2019","journal-title":"Onco Targets Ther"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02342","article-title":"Eprenetapopt plus azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia: A phase II study by the Groupe Francophone des My\u00e9lodysplasies (GFM)","volume":"39","author":"Cluzeau","year":"2021","journal-title":"J Clin Oncol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-19-0710","article-title":"Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia","volume":"10","author":"Pei","year":"2020","journal-title":"Cancer Discov"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.7150\/jca.113576","article-title":"The role of P53 in immune evasion and therapeutic strategies in hematologic Malignancies","volume":"16","author":"Wen","year":"2025","journal-title":"J Cancer"},{"key":"B70","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41392-021-00870-3","article-title":"Activation of RAS\/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia","volume":"7","author":"Zhang","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.22796","article-title":"The role of TP53 in acute myeloid leukemia: Challenges and opportunities","volume":"58","author":"Barbosa","year":"2019","journal-title":"Genes Chromosomes Cancer"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003300","article-title":"Selective drug combination vulnerabilities in STAT3- and TP53-mutant Malignant NK cells","volume":"5","author":"Parri","year":"2021","journal-title":"Blood Adv"},{"key":"B73","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41698-025-01249-1","article-title":"Venetoclax resistance in preclinical KMT2A-rearranged acute lymphoblastic leukemia models is characterized by high inter- and intra-model heterogeneity","volume":"10","author":"Richter","year":"2025","journal-title":"NPJ Precis Oncol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005859","article-title":"TP53 mutations confer resistance to hypomethylating agents and BCL-2 inhibition in myeloid neoplasms","volume":"6","author":"Schimmer","year":"2022","journal-title":"Blood Adv"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1275251","article-title":"Therapeutic biomarkers in acute myeloid leukemia: Functional and genomic approaches","volume":"14","author":"Bhatia","year":"2024","journal-title":"Front Oncol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.20517\/cdr.2025.228","article-title":"Multi-omics classification of acute myeloid leukemia guides drug combinations to overcome venetoclax resistance","volume":"9","author":"Yang","year":"2026","journal-title":"Cancer Drug Resist"},{"key":"B77","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s00277-026-06843-2","article-title":"Clinico-genomic characterization of RAS-mutant acute myeloid leukemia","volume":"105","author":"Yuan","year":"2026","journal-title":"Ann Hematol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024028239","article-title":"A CEBPB\/IL-1\u03b2\/TNF-\u03b1 feedback loop drives drug resistance to venetoclax and MDM2 inhibitors in monocytic leukemia","volume":"145","author":"Allen","year":"2025","journal-title":"Blood"},{"key":"B79","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1158\/2159-8290.cd-19-0117","article-title":"Targeting mitochondrial structure sensitizes acute myeloid leukemia to venetoclax treatment","volume":"9","author":"Chen","year":"2019","journal-title":"Cancer Discov"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.254623","article-title":"Monitoring of clonal evolution of acute myeloid leukemia identifies the leukemia subtype, clinical outcome and potential new drug targets for post-remission strategies or relapse","volume":"106","author":"Onecha","year":"2021","journal-title":"Haematologica"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1021\/acsptsci.4c00414","article-title":"Covalent fragments acting as tyrosine mimics for mutant p53-Y220C rescue by nucleophilic aromatic substitution","volume":"7","author":"Klett","year":"2024","journal-title":"ACS Pharmacol Transl Sci"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1021\/acsomega.3c08509","article-title":"Reconnaissance of allostery via the restoration of native p53 DNA-binding domain dynamics in Y220C mutant p53 tumor suppressor protein","volume":"9","author":"Han","year":"2024","journal-title":"ACS Omega"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5c00670","article-title":"Rezatapopt (PC14586): A first-in-class small molecule p53 Y220C mutant protein stabilizer in clinical trials","volume":"68","author":"Ma","year":"2025","journal-title":"J Med Chem"},{"key":"B84","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s12951-023-01867-6","article-title":"Precise pancreatic cancer therapy through targeted degradation of mutant p53 protein by cerium oxide nanoparticles","volume":"21","author":"Zhang","year":"2023","journal-title":"J Nanobiotechnology"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025028935","article-title":"Restoring p53 wild-type conformation in TP53-Y220C-mutant acute myeloid leukemia","volume":"146","author":"Carter","year":"2025","journal-title":"Blood"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14184519","article-title":"How I treat TP53-mutated acute myeloid leukemia and myelodysplastic syndromes","volume":"14","author":"Loschi","year":"2022","journal-title":"Cancers (Basel)"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1921345\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T04:49:02Z","timestamp":1784695742000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1921345\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":86,"alternative-id":["10.3389\/fonc.2026.1921345"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1921345","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]},"article-number":"1921345"}}